NYU LANGONE HEALTH

NYU Langone Health researchers successfully used rozanolixizumab, an FcRn inhibitor, to prevent congenital heart block in a high-risk pregnancy, marking the first reported case of this therapeutic approach.

Early phase clinical trials of CAR-T cellular therapy for systemic lupus erythematosus are showing unprecedented results, with patients experiencing quick resolution of clinical and laboratory abnormalities.

SurgiVance Inc. received a $2,245,000 National Cancer Institute Small Business Innovation Research Direct-to-Phase II grant to commercialize its "pathology lab-in-a-box" technology.

An 8-year-old boy with HPDL deficiency, a rare mitochondrial disease causing paralysis and often death, showed dramatic improvement after receiving an experimental treatment with 4-hydroxybenzoate (4-HB).

Researchers at NYU Langone Health developed a bispecific antibody called BiTS that targets both T cell receptors and LAG-3 checkpoints to selectively suppress autoimmune T cells.

Researchers analyzed genetic material from 1,225 metastatic melanoma patients and identified that those with mitochondrial haplogroup T (HG-T) were 3.46 times less likely to respond to checkpoint inhibitor therapy.

URO-1's SUREcore biopsy needle demonstrated 92% targeting accuracy compared to 36% for standard needles, representing a major advancement in prostate cancer diagnostics.

Circulating tumor DNA (ctDNA) monitoring can reliably identify minimal residual disease in patients with resected stage III melanoma, predicting high risk of early recurrence even when patients appear disease-free by radiographic measures.

A new Ultra-Rapid droplet digital PCR test can detect brain cancer cells in tissue samples within 15 minutes, providing surgeons with real-time feedback during operations.

NYU Langone researchers have discovered that BRCA2 acts as a molecular shield preventing PARP1 from binding to DNA damage sites, explaining why PARP inhibitors are effective only in certain cancer patients.